Phosplatin Therapeutics Reports Phase 1b Study Results of Immunogenic Cell Death Inducer PT-112 Plus PD-L1 Inhibitor avelumab in Metastatic Prostate Cancer at ASCO Annual Meeting ...Middle East

NEW YORK, May 20, 2021 /PRNewswire/ -- Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, today reported additional data in a sub-population of heavily pre-treated, patients with metastatic castrate-resistant prostate cancer (mCRPC)...

Hence then, the article about phosplatin therapeutics reports phase 1b study results of immunogenic cell death inducer pt 112 plus pd l1 inhibitor avelumab in metastatic prostate cancer at asco annual meeting was published today ( Thursday 20/05/2021 - 11:30 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Phosplatin Therapeutics Reports Phase 1b Study Results of Immunogenic Cell Death Inducer PT-112 Plus PD-L1 Inhibitor avelumab in Metastatic Prostate Cancer at ASCO Annual Meeting )

Also on site :

• Anne Schedeen Dies: Actress Who Played ‘ALF’s Mom Was 77
• Motorcyclist killed in crash with vehicle in Lombard: Police
• Shania Twain, 60, Shares the Menopause Surprise She Never Saw Coming